Extended-spectrum β-lactamase-producing Enterobacteriaceae in an italian intensive care unit: Clinical and therapeutical remarks

Journal of Chemotherapy

Volumn 16, Issue 2, 2004, Pages 145-150

  Carretto, E ^a,c   Emmi, V ^b,c   Barbarini, D ^a   Capra Marzani, F ^c   Bolongaro, A ^c   Braschi, A ^c,d   Marone, P ^a  

^a Laboratori Sperimentali di Ricerca   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Enterobacteriaceae; Epidemiology; ESBL; Extended spectrum beta lactamases; Intensive Care Unit; Proteus mirabilis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAM; BETA LACTAMASE; CARBAPENEM; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; QUINOLONE DERIVATIVE;

ARTICLE; BACTEREMIA; BACTERIAL STRAIN; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL FEATURE; CONTROLLED STUDY; DEVICE INFECTION; ENTEROBACTERIACEAE; INDWELLING CATHETER; INTENSIVE CARE UNIT; ITALY; KLEBSIELLA PNEUMONIAE; MORTALITY; NONHUMAN; PREVALENCE; PROTEUS MIRABILIS; URINARY TRACT INFECTION; WOUND INFECTION;

EID: 2942628342     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.2.145     Document Type: Article

References (29)

1. Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28(2): 302-7.
2. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14(4): 933-51.
3. Ambler RP. The structure of beta-lactamases. Phil Trans R Soc Lond Biol Sci 1980; 289(1036): 321-31.
4. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39(6): 1211-33.
5. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35(9): 1697-704.
6. Peña C, Pujol M, Ricart A et al. Risk factors for faecal carriage of Klebsiella pneumoniae producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. J Hosp Infect 1997; 35(1): 9-16.
7. National Nosocomial Infection Surveillance (NNIS) System Report. Data summary from January 1990 - May 1999, issued June 1999. Am J Infect Contr 1999; 27: 520-32.
8. Stobberingh EE, Arends J, Hoogkamp-Korstanje JA et al. Occurrence of extended-spectrum betalactamases (ESBL) in Dutch hospitals. Infection 1999; 27(6): 348-54.
9. Branger C, Lesimple AL, Bruneau B, Berry P, Lambert-Zechovsky N. Long-term investigation of the clonal dissemination of Klebsiella pneumoniae isolates producing extended-spectrum beta-lactamases in a university hospital. J Med Microbiol 1998; 47(3): 201-9.
10. Yagi T, Kurokawa H, Shibata N, Shibayama K, Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000; 184(1): 53-6.
11. Ho PL, Tsang DN, Que TL, Ho M, Yuen KY. Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among Escherichia coli and Klebsiella species in Hong Kong. APMIS 2000; 108(3): 237-40.
12. Fluit AC, Jones ME, Schmitz FJ, Acar J, Gupta R, Verhoef J. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998. Clin Infect Dis 2000; 30(3): 454-60.
13. Essack SY. Laboratory detection of extended-spectrum beta-lactamases (ESBLs). The need for a reliable, reproducible method. Diagn Microbiol Infect Dis 2000; 37(4): 293-5.
14. Hollander R, Ebke M, Barck H, von Pritzbuer E. Asymptomatic carriage of Klebsiella pneumoniae producing extended-spectrum beta-lactamase by patients in a neurological early rehabilitation unit: management of an outbreak. J Hosp Infect 2001; 48(3): 207-13.
15. Rebuck JA, Olsen KM, Fey PD, Langnas AN, Rupp ME. Characterization of an outbreak due to extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a pediatric intensive care unit transplant population. Clin Infect Dis 2000; 31(6): 1368-72.
16. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58.
17. Gruteke P, Goessens W, Van Gils J et al. Patterns of resistance associated with integrons, the extended-spectrum beta-lactamase SHV-5 gene, and a multidrug efflux pump of Klebsiella pneumoniae causing a nosocomial outbreak. J Clin Microbiol 2003; 41(3): 1161-6.
18. Yu WL, Jones RN, Hollis RJ et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002; 40(12): 4666-9.
19. Quale JM, Landman D, Bradford PA et al. Molecular epidemiology of a citywide outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae infection. Clin Infect Dis 2002; 35(7): 834-41.
20. Smith PB, Tomfohrde KM, Rhoden DL, Balows A. API system: a multitube micromethod for identification of Enterobacteriaceae. Appl Microbiol 1972; 24(3): 449-52.
21. National Committee of Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: twelfth informational supplement NCCLS, 2002.
22. Jarlier V, Nicolas MH, Fournier G, Philippon A. Extended broad-spectrum β-lactamases conferring transferable resistance to newer β-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867-78.
23. National Committee of Clinical Laboratory Standards. Fact sheet: laboratory detection of extended-spectrum beta-lactamases (ESBL). See: http://www.cdc.gov/ncidod/hip/Lab/FactSheet/esbl.htm.
24. Emori TG, Edwards JR, Culver DH et al. Accuracy of reporting nosocomial infections in intensive-care-unit patients to the National Nosocomial Infections Surveillance System: a pilot study. Infect Contr Hosp Epidemiol 1998; 19(5): 308-16.
25. Du B, Long Y, Liu H et al. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome. Intensive Care Med 2002; 28(12): 1718-23.
26. Babini GS, Livermore DM. Antimicrobial resistance amongst Klebsiella spp. collected from intensive care units in Southern and Western Europe in 1997-1998. J Antimicrob Chemother 2000; 45: 183-9.
27. De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: a two year survey. J Antimicrob Chemother 2000; 45: 537-9.
28. Bonfiglio G, Perilli M, Stefani S, Amicosante G, Nicoletti G. Prevalence of extended spectrum beta-lactamases among Enterobacteriaceae: an Italian survey. Int J Antimicrob Agents 2002; 19: 213-7.
29. Mutnick AH, Turner PJ, Jones RN. Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. J Chemother 2002; 14(3): 253-8.